The disclosure relates generally to medical devices and more particularly to medical devices that are adapted for use in percutaneous medical procedures including implantation into the left atrial appendage (LAA) of a heart.
The left atrial appendage is a small organ attached to the left atrium of the heart. During normal heart function, as the left atrium constricts and forces blood into the left ventricle, the left atrial appendage constricts and forces blood into the left atrium. The ability of the left atrial appendage to contract assists with improved filling of the left ventricle, thereby playing a role in maintaining cardiac output. However, in patients suffering from atrial fibrillation, the left atrial appendage may not properly contract or empty, causing stagnant blood to pool within its interior, which can lead to the undesirable formation of thrombi within the left atrial appendage.
The occurrence of thrombi in the left atrial appendage during atrial fibrillation may be due to stagnancy of the blood pool in the left atrial appendage. The blood may still be pulled out of the left atrium by the left ventricle, however less effectively due to the irregular contraction of the left atrium caused by atrial fibrillation. Therefore, instead of an active support of the blood flow by a contracting left atrium and left atrial appendage, filling of the left ventricle may depend primarily or solely on the suction effect created by the left ventricle. Further, the contraction of the left atrial appendage may not be in sync with the cycle of the left ventricle. For example, contraction of the left atrial appendage may be out of phase up to 180 degrees with the left ventricle, which may create significant resistance to the desired flow of blood. Further still, most left atrial appendage geometries are complex with large irregular surface areas and a narrow ostium or opening compared to the depth of the left atrial appendage. These aspects as well as others, taken individually or in various combinations, may lead to high flow resistance of blood out of the left atrial appendage and/or formation of thrombi within the left atrial appendage.
Thrombi forming in the left atrial appendage may break loose from this area and enter the blood stream. Thrombi that migrate through the blood vessels may eventually plug a smaller vessel downstream and thereby contribute to stroke or heart attack. Clinical studies have shown that the majority of blood clots in patients with atrial fibrillation originate in the left atrial appendage. As a treatment, medical devices have been developed which are deployed to close off the left atrial appendage. Over time, exposed surface(s) of an implant spanning the left atrial appendage may become covered with tissue (a process called endothelization), effectively removing the left atrial appendage from the circulatory system and reducing or eliminating the amount of thrombi which may enter the blood stream from the left atrial appendage. Of the known medical devices and methods, each has certain advantages and disadvantages. There is an ongoing need to provide alternative medical devices and introducers as well as alternative methods for manufacturing and using medical devices and introducers.
In a first aspect, an implant for occluding a left atrial appendage may comprise an expandable framework configured to shift between a collapsed configuration and an expanded configuration, wherein the expandable framework includes an attachment point configured to secure the expandable framework to a delivery device; and an occlusive element disposed on a proximal portion of the expandable framework, wherein the occlusive element covers the attachment point.
In addition or alternatively, the expandable framework includes a proximal hub.
In addition or alternatively, the attachment point is a pin extending laterally across the proximal hub.
In addition or alternatively, the implant may further include a fastening element securing the occlusive element to the pin.
In addition or alternatively, the implant may further include a plurality of anchor members configured to secure the implant to tissue within the left atrial appendage.
In addition or alternatively, the occlusive element includes a porous mesh.
In addition or alternatively, a system for occluding a left atrial appendage may comprise a delivery device including an outer sheath and an inner elongate member slidably disposed within a lumen of the outer sheath, and an implant configured to occlude the left atrial appendage. The implant may comprise an expandable framework configured to shift between a collapsed configuration when disposed within the outer sheath and an expanded configuration when disposed outside of the outer sheath, wherein the expandable framework includes an attachment point configured to secure the expandable framework to the delivery device; and an occlusive element disposed on a proximal portion of the expandable framework, wherein the occlusive element covers the attachment point.
In addition or alternatively, the system may further include a tether extending longitudinally within the inner elongate member, the tether engaging the attachment point in a delivery configuration.
In addition or alternatively, the tether extends through the occlusive element in the delivery configuration.
In addition or alternatively, the tether is disengaged from the attachment point in a released configuration.
In addition or alternatively, the system may further comprise a release mechanism disposed within the lumen of the inner elongate member, wherein the release mechanism is configured to sever the tether within the lumen of the inner elongate member.
In addition or alternatively, the release mechanism includes a cutting blade disposed within the inner elongate member.
In addition or alternatively, the system may further comprise a turnstile movably engaged with a proximal end of the inner elongate member.
In addition or alternatively, the attachment point may include a cam member extending laterally across a proximal hub of the expandable framework. The cam member may be configured to cooperate with a distal end of the inner elongate member.
In addition or alternatively, the tether extends around the cam member, such that axial translation of the tether is configured to angle the expandable framework relative to a central longitudinal axis of the delivery device.
In addition or alternatively, a method of occluding a left atrial appendage may comprise: advancing an implant configured to occlude the left atrial appendage into the left atrial appendage, wherein the implant comprises an expandable framework configured to shift between a collapsed configuration and an expanded configuration, wherein the expandable framework includes an attachment point configured to secure the expandable framework to a delivery device; and an occlusive element disposed on a proximal portion of the expandable framework, wherein the occlusive element covers the attachment point; deploying the implant within the left atrial appendage; and releasing the implant within the left atrial appendage. After releasing the implant, all metallic materials of the implant may be disposed distal of a proximal-facing surface of the occlusive element.
In addition or alternatively, releasing the implant includes severing a tether securing the implant to the delivery device.
In addition or alternatively, axial translation of the tether prior to severing the tether angles the expandable framework relative to a central longitudinal axis of the delivery device.
In addition or alternatively, rotation of a turnstile relative to a proximal end of the delivery device severs the tether.
In addition or alternatively, subsequent proximal retraction of the turnstile disengages the tether from the implant.
The above summary of some embodiments, aspects, and/or examples is not intended to describe each embodiment or every implementation of the present disclosure. The figures and the detailed description which follows more particularly exemplify these embodiments.
The disclosure may be more completely understood in consideration of the following detailed description of various embodiments in connection with the accompanying drawings, in which:
While aspects of the disclosure are amenable to various modifications and alternative forms, specifics thereof have been shown by way of example in the drawings and will be described in detail. It should be understood, however, that the intention is not to limit aspects of the disclosure to the particular embodiments described. On the contrary, the intention is to cover all modifications, equivalents, and alternatives falling within the spirit and scope of the disclosure.
The following description should be read with reference to the drawings, which are not necessarily to scale, wherein like reference numerals indicate like elements throughout the several views. The detailed description and drawings are intended to illustrate but not limit the claimed invention. Those skilled in the art will recognize that the various elements described and/or shown may be arranged in various combinations and configurations without departing from the scope of the disclosure. The detailed description and drawings illustrate example embodiments of the claimed invention. However, in the interest of clarity and ease of understanding, while every feature and/or element may not be shown in each drawing, the feature(s) and/or element(s) may be understood to be present regardless, unless otherwise specified.
For the following defined terms, these definitions shall be applied, unless a different definition is given in the claims or elsewhere in this specification.
All numeric values are herein assumed to be modified by the term “about,” whether or not explicitly indicated. The term “about”, in the context of numeric values, generally refers to a range of numbers that one of skill in the art would consider equivalent to the recited value (e.g., having the same function or result). In many instances, the term “about” may include numbers that are rounded to the nearest significant figure. Other uses of the term “about” (e.g., in a context other than numeric values) may be assumed to have their ordinary and customary definition(s), as understood from and consistent with the context of the specification, unless otherwise specified.
The recitation of numerical ranges by endpoints includes all numbers within that range, including the endpoints (e.g., 1 to 5 includes 1, 1.5, 2, 2.75, 3, 3.80, 4, and 5).
Although some suitable dimensions, ranges, and/or values pertaining to various components, features and/or specifications are disclosed, one of skill in the art, incited by the present disclosure, would understand desired dimensions, ranges, and/or values may deviate from those expressly disclosed.
As used in this specification and the appended claims, the singular forms “a”, “an”, and “the” include plural referents unless the content clearly dictates otherwise. As used in this specification and the appended claims, the term “or” is generally employed in its sense including “and/or” unless the content clearly dictates otherwise. It is to be noted that in order to facilitate understanding, certain features of the disclosure may be described in the singular, even though those features may be plural or recurring within the disclosed embodiment(s). Each instance of the features may include and/or be encompassed by the singular disclosure(s), unless expressly stated to the contrary. For simplicity and clarity purposes, not all elements of the disclosed invention are necessarily shown in each figure or discussed in detail below. However, it will be understood that the following discussion may apply equally to any and/or all of the components for which there are more than one, unless explicitly stated to the contrary. Additionally, not all instances of some elements or features may be shown in each figure for clarity.
Relative terms such as “proximal”, “distal”, “advance”, “retract”, variants thereof, and the like, may be generally considered with respect to the positioning, direction, and/or operation of various elements relative to a user/operator/manipulator of the device, wherein “proximal” and “retract” indicate or refer to closer to or toward the user and “distal” and “advance” indicate or refer to farther from or away from the user. In some instances, the terms “proximal” and “distal” may be arbitrarily assigned in an effort to facilitate understanding of the disclosure, and such instances will be readily apparent to the skilled artisan. Other relative terms, such as “upstream”, “downstream”, “inflow”, and “outflow” refer to a direction of fluid flow within a lumen, such as a body lumen, a blood vessel, or within a device.
The term “extent” may be understood to mean a greatest measurement of a stated or identified dimension, unless the extent or dimension in question is preceded by or identified as a “minimum”, which may be understood to mean a smallest measurement of the stated or identified dimension. For example, “outer extent” may be understood to mean an outer dimension, “radial extent” may be understood to mean a radial dimension, “longitudinal extent” may be understood to mean a longitudinal dimension, etc. Each instance of an “extent” may be different (e.g., axial, longitudinal, lateral, radial, circumferential, etc.) and will be apparent to the skilled person from the context of the individual usage. Generally, an “extent” may be considered a greatest possible dimension measured according to the intended usage, while a “minimum extent” may be considered a smallest possible dimension measured according to the intended usage. In some instances, an “extent” may generally be measured orthogonally within a plane and/or cross-section, but may be, as will be apparent from the particular context, measured differently—such as, but not limited to, angularly, radially, circumferentially (e.g., along an arc), etc.
The terms “monolithic” and “unitary” shall generally refer to an element or elements made from or consisting of a single structure or base unit/element. A monolithic and/or unitary element shall exclude structure and/or features made by assembling or otherwise joining multiple discrete elements together.
It is noted that references in the specification to “an embodiment”, “some embodiments”, “other embodiments”, etc., indicate that the embodiment(s) described may include a particular feature, structure, or characteristic, but every embodiment may not necessarily include the particular feature, structure, or characteristic. Moreover, such phrases are not necessarily referring to the same embodiment. Further, when a particular feature, structure, or characteristic is described in connection with an embodiment, it would be within the knowledge of one skilled in the art to effect the particular feature, structure, or characteristic in connection with other embodiments, whether or not explicitly described, unless clearly stated to the contrary. That is, the various individual elements described below, even if not explicitly shown in a particular combination, are nevertheless contemplated as being combinable or arrangeable with each other to form other additional embodiments or to complement and/or enrich the described embodiment(s), as would be understood by one of ordinary skill in the art.
For the purpose of clarity, certain identifying numerical nomenclature (e.g., first, second, third, fourth, etc.) may be used throughout the description and/or claims to name and/or differentiate between various described and/or claimed features. It is to be understood that the numerical nomenclature is not intended to be limiting and is exemplary only. In some embodiments, alterations of and deviations from previously-used numerical nomenclature may be made in the interest of brevity and clarity. That is, a feature identified as a “first” element may later be referred to as a “second” element, a “third” element, etc. or may be omitted entirely, and/or a different feature may be referred to as the “first” element. The meaning and/or designation in each instance will be apparent to the skilled practitioner.
The following figures illustrate selected components and/or arrangements of an implant for occluding the left atrial appendage, a system for occluding the left atrial appendage, and/or methods of using the implant and/or the system. It should be noted that in any given figure, some features may not be shown, or may be shown schematically, for simplicity. Additional details regarding some of the components of the implant and/or the system may be illustrated in other figures in greater detail. While discussed in the context of occluding the left atrial appendage, the implant and/or the system may also be used for other interventions and/or percutaneous medical procedures within a patient. Similarly, the devices and methods described herein with respect to percutaneous deployment may be used in other types of surgical procedures, as appropriate. For example, the implant and/or the system could be used in a non-percutaneous procedure. Devices and methods in accordance with the disclosure may also be adapted and configured for other uses within the anatomy.
The system 100 and/or the delivery device may include an inner elongate member 130 slidably disposed within the lumen 120 of the outer sheath 110. In some embodiments, the inner elongate member 130 may include a lumen extending axially and/or longitudinally from a proximal end of the inner elongate member 130 to a distal end of the inner elongate member 130. In some embodiments, the inner elongate member 130 may include a plurality of lumens extending axially and/or longitudinally from a proximal end of the inner elongate member 130 to a distal end of the inner elongate member 130. In at least some embodiments, the inner elongate member 130 and/or the outer sheath 110 may include one or more seals and/or sealing structures within the lumen or lumens thereof to reduce and/or prevent fluid (e.g., blood) flow through the lumen or lumens thereof from the distal end to the proximal end. The inner elongate member 130 may be axially and/or longitudinally movable relative to the outer sheath 110. In some embodiments, the inner elongate member 130 may be used to advance (e.g., push) the implant 200 out of the lumen 120 of the outer sheath 110. In some embodiments, the inner elongate member 130 may be used to hold and/or maintain an axial and/or longitudinal position of the implant 200 as the outer sheath 110 is retracted and/or axially translated proximally relative to the implant 200 to expose the implant 200 from the lumen 120 of the outer sheath 110. Some suitable, but non-limiting, examples of materials for the inner elongate member 130 are discussed below.
The system 100 and/or the delivery device may further include a tether 140 extending longitudinally within the lumen (or within at least one of the plurality of lumens) of the inner elongate member 130. In some embodiments, the tether 140 may include a first longitudinally extending portion 142 and a second longitudinally extending portion 144. In some embodiments, the first longitudinally extending portion 142 and/or the second longitudinally extending portion 144 may extend completely through an entire length of the lumen of the inner elongate member 130. In some embodiments, the second longitudinally extending portion 144 may extend along only a portion of the entire length (e.g., less than the entire length) of the lumen of the inner elongate member 130. In some embodiments, the first longitudinally extending portion 142 may extend completely through an entire length of a first lumen of the plurality of lumens of the inner elongate member 130. In some embodiments, the second longitudinally extending portion 144 may extend completely through an entire length of a second lumen of the plurality of lumens of the inner elongate member 130. In some embodiments, the second longitudinally extending portion 144 may extend along only a portion of the entire length (e.g., less than the entire length) of the second lumen of the plurality of lumens of the inner elongate member 130. Some suitable, but non-limiting, examples of materials for the tether 140 are discussed below.
In some embodiments, the implant 200 includes an occlusive element 290 disposed and/or positioned on, over, and/or around at least a portion of the expandable framework 210, as shown in
In some embodiments, the implant 200 and/or the expandable framework 210 may include a proximal hub 220 and/or a distal hub 230. The plurality of interconnected struts and/or frame segments may be fixedly attached to and/or at the proximal hub 220 and/or the distal hub 230. In some embodiments, the expandable framework 210 may include an attachment point 240 configured to secure the expandable framework 210 to the delivery device and/or the tether 140. In some embodiments, the attachment point 240 may be a pin 222 extending laterally across the proximal hub 220, as seen in the top view of
In some embodiments, the implant 200 may include a fastening element 250 securing the occlusive element 290 to the pin 222 and/or the attachment point 240, as seen in the top view of
In some embodiments, the occlusive element 290 may include a surface treatment configured to promote endothelization on and/or across the occlusive element 290. In some embodiments, the occlusive element 290 may include the surface treatment disposed on and/or surrounding a portion of an outer surface and/or a proximally-facing surface of the occlusive element 290. In some embodiments, the occlusive element 290 may include the surface treatment disposed on and/or surrounding an entire outer surface and/or an entire proximally-facing surface of the occlusive element 290. In some embodiments, the occlusive element 290 may be elastic and/or stretchable to accommodate changes in shape and/or size of the expandable framework 210 when the expandable framework 210 is shifted toward and/or into the expanded configuration. Some suitable, but non-limiting, examples of materials for the expandable framework 210, the plurality of interconnected struts and/or frame segments, the plurality of anchor members 212, the proximal hub 220, the pin 222, the distal hub 230, the fastening element 250, and/or the occlusive element 290 are discussed below.
As seen in
Turning now to
In some embodiments, the tether 140 may extend around the pin 222 and/or the attachment point 240 one time without wrapping and/or completely encircling the pin 222 and/or the attachment point 240. However, it is contemplated that in some embodiments, the tether 140 may wrap around the pin 222 and/or the attachment point 240 multiple times. The first longitudinally extending portion 142 may be disposed on a first side of the pin 222 and/or the attachment point 240, and the second longitudinally extending portion 144 may be disposed on a second side of the pin 222 and/or the attachment point 240. While not explicitly illustrated in
The tether 140 may be used to secure the implant 200 to the delivery device. Tension applied to the tether 140 relative to the inner elongate member 130 may pull the implant 200 and/or the expandable framework 210 into engagement with and/or against a distal end of the inner elongate member 130, as seen in
In some embodiments, the second longitudinally extending portion 144 of the tether 140 may be secured and/or fixedly attached to the inner elongate member 130 at a tether attachment point 148 proximate a distal end of the inner elongate member 130, such as by adhesive bonding, mechanical attachment, or other suitable means. In some embodiments, a distal end of the tether 140 may be secured and/or fixedly attached to the inner elongate member 130 at the tether attachment point 148 proximate the distal end of the inner elongate member 130. Applying tension to the first longitudinally extending portion 142 of the tether 140 may pull the implant 200 and/or the expandable framework 210 into engagement with and/or against the distal end of the inner elongate member 130.
The system 100 may further include a release mechanism disposed within the delivery device, the lumen of the outer sheath 110, and/or the lumen of the inner elongate member 130. For the purpose of illustration, the release mechanism is shown in
In some embodiments, the release mechanism may include a cutting blade 150 disposed within the delivery device, the inner elongate member 130, and/or the outer sheath 110. In the configuration shown in
In another configuration, the release mechanism may include a cutting blade 170 disposed within the delivery device, the inner elongate member 130, and/or the outer sheath 110. In the configuration shown in
The tether 140 may extend through the lumen of the inner elongate member 130 and/or the outer sheath 110. The second longitudinally extending portion 144 may be fixedly attached to the turnstile 180 at a tether attachment point 184. The first longitudinally extending portion 142 may extend through the turnstile 180 to engage with a first adjustment element 186. The first adjustment element 186 may be configured to translate axially relative to the turnstile 180 to adjust tension applied to the tether 140. In some embodiments, the first adjustment element 186 may include a threaded member, a spring member, a slide member, a cam member, or other suitable means of applying tension to the tether 140, such as via axial translation. In some embodiments, the second longitudinally extending portion 144 may extend through the turnstile 180 to engage with a second adjustment element 188 (e.g.,
When the user is ready to release the implant 200, the turnstile 180 may be rotated relative to a proximal end of the delivery device, the inner elongate member 130, and/or the outer sheath 110 to engage the tether 140 with the cutting blade 170, thereby severing the tether 140, as shown in
In some embodiments, the system 100 may include a feature or features that permit the implant 200 to be angled relative to a central longitudinal axis of the delivery device, the inner elongate member 130, and/or the outer sheath 110, as seen in
The tether 140 may engage the cam member 224 and/or the attachment point 240 in the delivery configuration of the system 100, as shown in
In some embodiments, the cam member engaging portion 143 of the tether 140 may extend around the convex distal side of the cam member 224 and/or the attachment point 240 one time without wrapping and/or completely encircling the cam member 224 and/or the attachment point 240. However, it is contemplated that in some embodiments, the cam member engaging portion 143 of the tether 140 may wrap around the cam member 224 and/or the attachment point 240 multiple times. The first longitudinally extending portion 142 may be disposed on a first lateral side of the cam member 224 and/or the attachment point 240, and the second longitudinally extending portion 144 may be disposed on a second lateral side of the cam member 224 and/or the attachment point 240. Both the first longitudinally extending portion 142 and the second longitudinally extending portion 144 may extend proximally away from the cam member 224 and/or the attachment point 240.
The tether 140 may be used to secure the implant 200 to the delivery device. Turning back to
In some embodiments, the concave proximal side of the cam member 224 may function as a rocker and/or slider feature that cooperates with the distal end of the inner elongate member 130. Tension applied to and/or axial translation in a proximal direction of the first longitudinally extending portion 142 using the first adjustment element 186 (and/or slack from loosening tension applied to and/or axial translation in a distal direction of the second longitudinally extending portion 144 using the second adjustment element 188) may shift the cam member 224, the expandable framework 210, and/or the implant 200 laterally relative to the central longitudinal axis of the delivery device, the inner elongate member 130, and/or the outer sheath 110. As such, tension applied to and/or axial translation in the proximal direction of the first longitudinally extending portion 142 using the first adjustment element 186 (and/or slack from loosening tension applied to and/or axial translation in the distal direction of the second longitudinally extending portion 144 using the second adjustment element 188 may be configured to angle the expandable framework 210 relative to the central longitudinal axis of the delivery device, the inner elongate member 130, and/or the outer sheath 110, as seen in
Similarly, tension applied to and/or axial translation in a proximal direction of the to second longitudinally extending portion 144 using the second adjustment element 188 (and/or slack from loosening tension applied to and/or axial translation in a distal direction of the first longitudinally extending portion 142 using the first adjustment element 186) may shift the cam member 224, the expandable framework 210, and/or the implant 200 laterally relative to the central longitudinal axis of the delivery device, the inner elongate member 130, and/or the outer sheath 110. As such, tension applied to and/or axial translation in the proximal direction of the second longitudinally extending portion 144 using the second adjustment element 188 (and/or slack from loosening tension applied to and/or axial translation in the distal direction of the first longitudinally extending portion 142 using the first adjustment element 186) may be configured to angle the expandable framework 210 relative to the central longitudinal axis of the delivery device, the inner elongate member 130, and/or the outer sheath 110, as seen in
A method of occluding the left atrial appendage 50 may comprise advancing the implant 200 configured to occlude the left atrial appendage 50 in the delivery configuration, within a lumen of the delivery device and/or the outer sheath 110 with the expandable framework 210 in the collapsed configuration (e.g.,
The method may include deploying the implant 200 within the left atrial appendage 50, as seen in
The method may include releasing the implant 200 within the left atrial appendage 50. In some embodiments, releasing the implant 200 may include severing the tether 140 securing the implant 200 to the delivery device.
In some embodiments, the implant 200 and/or the expandable framework 210 may be oriented at an oblique angle to the generally longitudinal axis of the left atrial appendage 50. Engagement of the distal end of the inner elongate member 130 with the cam member 224 may permit and/or facilitate off-axis orientation of the implant 200 and/or the expandable framework 210 relative to the generally longitudinal axis of the left atrial appendage 50, which may ease positioning, implantation, and/or sealing within an irregularly-shaped and/or oriented left atrial appendage 50.
After releasing the implant 200, all metallic materials of the implant 200 may be disposed distal of a proximal-facing surface 292 of the occlusive element 290, such that all metallic materials are effectively removed from the blood stream and/or are no longer exposed to moving fluid and/or blood within the circulatory system (including the left atrium of the heart) of the patient. In some embodiments, after releasing the implant 200, all other structure of the implant 200 and/or the expandable framework 210 may be disposed distal of the proximal-facing surface 292 of the occlusive element 290, such that only the proximal-facing surface 292 of the occlusive element 290 remains exposed to and/or in intimate contact with the blood stream and/or moving fluid and/or blood within the circulatory system (including the left atrium of the heart) of the patient. For example, the expandable framework 210, the proximal hub 220, the distal hub 230, the attachment point 240, the plurality of anchor members 212, etc. may be disposed distal of the proximal-facing surface 292 of the occlusive element 290.
After release of the implant 200, subsequent proximal retraction of the turnstile 180 relative to the proximal end of the delivery device (e.g.,
In some embodiments, the system 100 may include a feature or features that permit the implant 200 to be angled relative to the central longitudinal axis of the delivery device, the inner elongate member 130, and/or the outer sheath 110, as seen in
The tether 140 may engage the cam member 224 and/or the attachment point 240 in the delivery configuration of the system 100. The tether 140 may extend through the occlusive element 290, as described herein, in the delivery configuration of the system 100. The tether 140 may extend through two or more of the plurality of pores, openings, and/or apertures extending through the occlusive element 290 from the first side of the occlusive element 290 to the second side of the occlusive element 290. For example, the tether 140 may avoid piercing and/or otherwise compromising the integrity of the occlusive element 290 by passing through existing pores, openings, and/or apertures through the occlusive element 290. The tether 140 may extend around the cam member 224 and/or the attachment point 240. The first longitudinally extending portion 142 may extend through a first pore, opening, and/or aperture, and/or the second longitudinally extending portion 144 may extend through a second pore, opening, and/or aperture different from the first pore, opening, and/or aperture. A cam member engaging portion 143 of the tether 140 may extend around the cam member 224 and/or the attachment point 240 between the first longitudinally extending portion 142 and the second longitudinally extending portion 144.
In some embodiments, the inner elongate member 130 may include a rotatable wheel 190 protruding from the inner elongate member 130 such that the rotatable wheel 190 may be rotated clockwise and/or counterclockwise (as viewed from the side of the system 100 and/or the inner elongate member 130), as seen in
In some embodiments, the concave proximal side of the cam member 224 may function as a rocker and/or slider feature that cooperates with the distal end of the inner elongate member 130. Tension applied to and/or axial translation in a proximal direction of the first longitudinally extending portion 142 and/or tension applied to and/or axial translation in a distal direction of the second longitudinally extending portion 144, or vice versa, using the rotatable wheel 190 may shift the cam member 224, the expandable framework 210, and/or the implant 200 laterally relative to the central longitudinal axis of the delivery device, the inner elongate member 130, and/or the outer sheath 110, similar to other configurations described herein. As such, applied to and/or axial translation in a proximal direction of the first longitudinally extending portion 142 and/or tension applied to and/or axial translation in a distal direction of the second longitudinally extending portion 144, or vice versa, using the rotatable wheel 190 may be configured to angle the expandable framework 210 relative to the central longitudinal axis of the delivery device, the inner elongate member 130, and/or the outer sheath 110 (e.g.,
In at least some embodiments, the inner elongate member 130 may include a tether release element 196 configured to sever the tether 140, as seen in
The materials that can be used for the various components of the system 100 and the implant 200, and the various elements thereof, disclosed herein may include those commonly associated with medical devices. For simplicity purposes, the following discussion makes reference to the system 100 and the implant 200. However, this is not intended to limit the devices and methods described herein, as the discussion may be applied to other elements, members, components, or devices disclosed herein, such as, but not limited to, the delivery device, the outer sheath, the inner elongate member, the tether, the release mechanism, the cutting blade, the adjustment element, the expandable framework, the anchor members, the proximal hub, the distal hub, the pin, the cam member, the occlusive element, and/or elements or components thereof.
In some embodiments, the system 100 and the implant 200, and/or components thereof, may be made from a metal, metal alloy, polymer (some examples of which are disclosed below), a metal-polymer composite, ceramics, combinations thereof, and the like, or other suitable material.
Some examples of suitable polymers may include polytetrafluoroethylene (PTFE), ethylene tetrafluoroethylene (ETFE), fluorinated ethylene propylene (FEP), polyoxymethylene (POM, for example, DELRIN® available from DuPont), polyether block ester, polyurethane (for example, Polyurethane 85A), polypropylene (PP), polyvinylchloride (PVC), polyether-ester (for example, ARNITEL® available from DSM Engineering Plastics), ether or ester based copolymers (for example, butylene/poly(alkylene ether) phthalate and/or other polyester elastomers such as HYTREL® available from DuPont), polyamide (for example, DURETHAN® available from Bayer or CRISTAMID® available from Elf Atochem), elastomeric polyamides, block polyamide/ethers, polyether block amide (PEBA, for example available under the trade name PEBAX®), ethylene vinyl acetate copolymers (EVA), silicones, polyethylene (PE), Marlex high-density polyethylene, Marlex low-density polyethylene, linear low density polyethylene (for example REXELL®), polyester, polybutylene terephthalate (PBT), polyethylene terephthalate (PET), polytrimethylene terephthalate, polyethylene naphthalate (PEN), polyetheretherketone (PEEK), polyimide (PI), polyetherimide (PEI), polyphenylene sulfide (PPS), polyphenylene oxide (PPO), poly paraphenylene terephthalamide (for example, KEVLAR®), polysulfone, nylon, nylon-12 (such as GRILAMID® available from EMS American Grilon), perfluoro(propyl vinyl ether) (PFA), ethylene vinyl alcohol, polyolefin, polystyrene, epoxy, polyvinylidene chloride (PVdC), poly(styrene-b-isobutylene-b-styrene) (for example, SIBS and/or SIBS 50A), polycarbonates, polyurethane silicone copolymers (for example, ElastEon® from Aortech Biomaterials or ChronoSil® from AdvanSource Biomaterials), biocompatible polymers, other suitable materials, or mixtures, combinations, copolymers thereof, polymer/metal composites, and the like. In some embodiments the sheath can be blended with a liquid crystal polymer (LCP). For example, the mixture can contain up to about 6 percent LCP.
Some examples of suitable metals and metal alloys include stainless steel, such as 304V, 304L, and 316LV stainless steel; mild steel; nickel-titanium alloy such as linear-elastic and/or super-elastic nitinol; other nickel alloys such as nickel-chromium-molybdenum alloys (e.g., UNS: N06625 such as INCONEL® 625, UNS: N06022 such as HASTELLOY® C-22®, UNS: N10276 such as HASTELLOY® C276®, other HASTELLOY® alloys, and the like), nickel-copper alloys (e.g., UNS: N04400 such as MONEL® 400, NICKELVAC® 400, NICORROS® 400, and the like), nickel-cobalt-chromium-molybdenum alloys (e.g., UNS: R30035 such as MP35-N® and the like), nickel-molybdenum alloys (e.g., UNS: N10665 such as HASTELLOY® ALLOY B2®), other nickel-chromium alloys, other nickel-molybdenum alloys, other nickel-cobalt alloys, other nickel-iron alloys, other nickel-copper alloys, other nickel-tungsten or tungsten alloys, and the like; cobalt-chromium alloys; cobalt-chromium-molybdenum alloys (e.g., UNS: R30003 such as ELGILOY®, PHYNOX®, and the like); platinum enriched stainless steel; titanium; platinum; palladium; gold; combinations thereof; or any other suitable material.
In some embodiments, a linear elastic and/or non-super-elastic nickel-titanium alloy may be in the range of about 50 to about 60 weight percent nickel, with the remainder being essentially titanium. In some embodiments, the composition is in the range of about 54 to about 57 weight percent nickel. One example of a suitable nickel-titanium alloy is FHP-NT alloy commercially available from Furukawa Techno Material Co. of Kanagawa, Japan. Other suitable materials may include ULTANIUM™ (available from Neo-Metrics) and GUM METAL™ (available from Toyota). In some other embodiments, a superelastic alloy, for example a superelastic nitinol can be used to achieve desired properties.
In at least some embodiments, portions or all of the system 100 and the implant 200, and/or components thereof, may also be doped with, made of, or otherwise include a radiopaque material. Radiopaque materials are understood to be materials capable of producing a relatively bright image on a fluoroscopy screen or another imaging technique during a medical procedure. This relatively bright image aids the user of the system 100 and the implant 200 in determining its location. Some examples of radiopaque materials can include, but are not limited to, gold, platinum, palladium, tantalum, tungsten alloy, polymer material loaded with a radiopaque filler, and the like. Additionally, other radiopaque marker bands and/or coils may also be incorporated into the design of the system 100 and the implant 200 to achieve the same result.
In some embodiments, a degree of Magnetic Resonance Imaging (Mill) compatibility is imparted into the system 100 and the implant 200 and/or other elements disclosed herein. For example, the system 100 and the implant 200, and/or components or portions thereof, may be made of a material that does not substantially distort the image and create substantial artifacts (i.e., gaps in the image). Certain ferromagnetic materials, for example, may not be suitable because they may create artifacts in an MM image. The system 100 and the implant 200, or portions thereof, may also be made from a material that the MM machine can image. Some materials that exhibit these characteristics include, for example, tungsten, cobalt-chromium-molybdenum alloys (e.g., UNS: R30003 such as ELGILOY®, PHYNOX®, and the like), nickel-cobalt-chromium-molybdenum alloys (e.g., UNS: R30035 such as MP35-N® and the like), nitinol, and the like, and others.
In some embodiments, the system 100 and the implant 200 and/or other elements disclosed herein may include a fabric material disposed over or within the structure. The fabric material may be composed of a biocompatible material, such a polymeric material or biomaterial, adapted to promote tissue ingrowth. In some embodiments, the fabric material may include a bioabsorbable material. Some examples of suitable fabric materials include, but are not limited to, polyethylene glycol (PEG), nylon, polytetrafluoroethylene (PTFE, ePTFE), a polyolefinic material such as a polyethylene, a polypropylene, polyester, polyurethane, and/or blends or combinations thereof.
In some embodiments, the system 100 and the implant 200 and/or other elements disclosed herein may include and/or be formed from a textile material. Some examples of suitable textile materials may include synthetic yarns that may be flat, shaped, twisted, textured, pre-shrunk or un-shrunk. Synthetic biocompatible yarns suitable for use in the present invention include, but are not limited to, polyesters, including polyethylene terephthalate (PET) polyesters, polypropylenes, polyethylenes, polyurethanes, polyolefins, polyvinyls, polymethylacetates, polyamides, naphthalene dicarboxylene derivatives, natural silk, and polytetrafluoroethylenes. Moreover, at least one of the synthetic yarns may be a metallic yarn or a glass or ceramic yarn or fiber. Useful metallic yarns include those yarns made from or containing stainless steel, platinum, gold, titanium, tantalum or a Ni-Co-Cr-based alloy. The yarns may further include carbon, glass or ceramic fibers. Desirably, the yarns are made from thermoplastic materials including, but not limited to, polyesters, polypropylenes, polyethylenes, polyurethanes, polynaphthalenes, polytetrafluoroethylenes, and the like. The yarns may be of the multifilament, monofilament, or spun-types. The type and denier of the yarn chosen may be selected in a manner which forms a biocompatible and implantable prosthesis and, more particularly, a vascular structure having desirable properties.
In some embodiments, the system 100 and the implant 200 and/or other elements disclosed herein may include and/or be treated with a suitable therapeutic agent. Some examples of suitable therapeutic agents may include anti-thrombogenic agents (such as heparin, heparin derivatives, urokinase, and PPack (dextrophenylalanine proline arginine chloromethylketone)); anti-proliferative agents (such as enoxaparin, angiopeptin, monoclonal antibodies capable of blocking smooth muscle cell proliferation, hirudin, and acetylsalicylic acid); anti-inflammatory agents (such as dexamethasone, prednisolone, corticosterone, budesonide, estrogen, sulfasalazine, and mesalamine); antineoplastic/antiproliferative/anti-mitotic agents (such as paclitaxel, 5-fluorouracil, cisplatin, vinblastine, vincristine, epothilones, endostatin, angiostatin and thymidine kinase inhibitors); anesthetic agents (such as lidocaine, bupivacaine, and ropivacaine); anti-coagulants (such as D-Phe-Pro-Arg chloromethyl keton, an RGD peptide-containing compound, heparin, anti-thrombin compounds, platelet receptor antagonists, anti-thrombin antibodies, anti-platelet receptor antibodies, aspirin, prostaglandin inhibitors, platelet inhibitors, and tick antiplatelet peptides); vascular cell growth promoters (such as growth factor inhibitors, growth factor receptor antagonists, transcriptional activators, and translational promoters); vascular cell growth inhibitors (such as growth factor inhibitors, growth factor receptor antagonists, transcriptional repressors, translational repressors, replication inhibitors, inhibitory antibodies, antibodies directed against growth factors, bifunctional molecules consisting of a growth factor and a cytotoxin, bifunctional molecules consisting of an antibody and a cytotoxin); cholesterol-lowering agents; vasodilating agents; and agents which interfere with endogenous vasoactive mechanisms.
It should be understood that this disclosure is, in many respects, only illustrative. Changes may be made in details, particularly in matters of shape, size, and arrangement of steps without exceeding the scope of the invention. This may include, to the extent that it is appropriate, the use of any of the features of one example embodiment being used in other embodiments. The invention's scope is, of course, defined in the language in which the appended claims are expressed.
This application claims the benefit of priority of U.S. Provisional Application No. 62/875,040 filed Jul. 17, 2019, the entire disclosure of which is hereby incorporated by reference.
Number | Name | Date | Kind |
---|---|---|---|
178283 | French | Jun 1876 | A |
1967318 | Monahan | Jul 1934 | A |
3402710 | Paleschuck | Sep 1968 | A |
3540431 | Mobin-Uddin | Nov 1970 | A |
3557794 | Van Patten | Jan 1971 | A |
3638652 | Kelley | Feb 1972 | A |
3811449 | Gravlee et al. | May 1974 | A |
3844302 | Klein | Oct 1974 | A |
3874388 | King et al. | Apr 1975 | A |
4007743 | Blake | Feb 1977 | A |
4108420 | West et al. | Aug 1978 | A |
4175545 | Termanini | Nov 1979 | A |
4309776 | Berguer | Jan 1982 | A |
4341218 | Ü | Jul 1982 | A |
4364392 | Strother et al. | Dec 1982 | A |
4425908 | Simon | Jan 1984 | A |
4545367 | Tucci | Oct 1985 | A |
4585000 | Hershenson | Apr 1986 | A |
4603693 | Conta et al. | Aug 1986 | A |
4611594 | Grayhack et al. | Sep 1986 | A |
4619246 | Molgaard-Nielsen et al. | Oct 1986 | A |
4638803 | Rand et al. | Jan 1987 | A |
4665906 | Jervis | May 1987 | A |
4681588 | Ketharanathan et al. | Jul 1987 | A |
4710192 | Liotta et al. | Dec 1987 | A |
4718417 | Kittrell et al. | Jan 1988 | A |
4759348 | Cawood et al. | Jul 1988 | A |
4781177 | Lebigot | Nov 1988 | A |
4793348 | Palmaz | Dec 1988 | A |
4827907 | Tashiro | May 1989 | A |
4832055 | Palestrant | May 1989 | A |
4873978 | Ginsburg | Oct 1989 | A |
4917089 | Sideris | Apr 1990 | A |
4921484 | Hillstead | May 1990 | A |
4960412 | Fink | Oct 1990 | A |
4966150 | Etienne et al. | Oct 1990 | A |
4998972 | Chin et al. | Mar 1991 | A |
5037810 | Saliba, Jr. | Aug 1991 | A |
5041090 | Scheglov et al. | Aug 1991 | A |
5041093 | Chu | Aug 1991 | A |
5042707 | Taheri | Aug 1991 | A |
5053009 | Herzberg | Oct 1991 | A |
5064435 | Porter | Nov 1991 | A |
5071407 | Termin et al. | Dec 1991 | A |
5078736 | Behl | Jan 1992 | A |
5098440 | Hillstead | Mar 1992 | A |
5108418 | Lefebvre | Apr 1992 | A |
5108420 | Marks | Apr 1992 | A |
5108474 | Riedy et al. | Apr 1992 | A |
5116360 | Pinchuk et al. | May 1992 | A |
5122136 | Guglielmi et al. | Jun 1992 | A |
5171259 | Inoue | Dec 1992 | A |
5171383 | Sagaye et al. | Dec 1992 | A |
5176692 | Wilk et al. | Jan 1993 | A |
5192301 | Kamiya et al. | Mar 1993 | A |
5211658 | Clouse | May 1993 | A |
5234458 | Metais | Aug 1993 | A |
5256146 | Ensminger et al. | Oct 1993 | A |
5258000 | Gianturco | Nov 1993 | A |
5258042 | Mehta | Nov 1993 | A |
5279539 | Bohan et al. | Jan 1994 | A |
5284488 | Sideris | Feb 1994 | A |
5304184 | Hathaway et al. | Apr 1994 | A |
5306234 | Johnson | Apr 1994 | A |
5312341 | Turi | May 1994 | A |
5329942 | Gunther et al. | Jul 1994 | A |
5334217 | Das | Aug 1994 | A |
5344439 | Otten | Sep 1994 | A |
5350398 | Pavcnik et al. | Sep 1994 | A |
5350399 | Erlebacher et al. | Sep 1994 | A |
5353784 | Nady-Mohamed | Oct 1994 | A |
5366460 | Eberbach | Nov 1994 | A |
5366504 | Andersen et al. | Nov 1994 | A |
5370657 | Irie | Dec 1994 | A |
5375612 | Cottenceau et al. | Dec 1994 | A |
5397331 | Himpens et al. | Mar 1995 | A |
5397355 | Marin et al. | Mar 1995 | A |
5409444 | Kensey et al. | Apr 1995 | A |
5417699 | Klein et al. | May 1995 | A |
5421832 | Lefebvre | Jun 1995 | A |
5425744 | Fagan et al. | Jun 1995 | A |
5427119 | Swartz et al. | Jun 1995 | A |
5433727 | Sideris | Jul 1995 | A |
5443454 | Tanabe et al. | Aug 1995 | A |
5443478 | Purdy et al. | Aug 1995 | A |
5451235 | Lock et al. | Sep 1995 | A |
5454365 | Bonutti | Oct 1995 | A |
5464408 | Duc | Nov 1995 | A |
5469867 | Schmitt | Nov 1995 | A |
5490856 | Person et al. | Feb 1996 | A |
5497774 | Swartz et al. | Mar 1996 | A |
5499975 | Cope et al. | Mar 1996 | A |
5499995 | Teirstein | Mar 1996 | A |
5522790 | Moll et al. | Jun 1996 | A |
5522822 | Phelps et al. | Jun 1996 | A |
5522836 | Palermo | Jun 1996 | A |
5527322 | Klein et al. | Jun 1996 | A |
5527338 | Purdy | Jun 1996 | A |
5558093 | Pomeranz et al. | Sep 1996 | A |
5558652 | Henke | Sep 1996 | A |
5569204 | Cramer et al. | Oct 1996 | A |
5591196 | Marin et al. | Jan 1997 | A |
5614204 | Cochrum | Mar 1997 | A |
5634936 | Linden et al. | Jun 1997 | A |
5634942 | Chevillon et al. | Jun 1997 | A |
5637097 | Yoon | Jun 1997 | A |
5643282 | Kieturakis | Jul 1997 | A |
5643292 | Hart | Jul 1997 | A |
5649953 | Lefebvre | Jul 1997 | A |
5653690 | Booth et al. | Aug 1997 | A |
5662671 | Barbut et al. | Sep 1997 | A |
5669933 | Simon et al. | Sep 1997 | A |
5681345 | Euteneuer | Oct 1997 | A |
5681347 | Cathcart et al. | Oct 1997 | A |
5683411 | Kavteladze et al. | Nov 1997 | A |
5690671 | McGurk et al. | Nov 1997 | A |
5693067 | Purdy | Dec 1997 | A |
5695525 | Mulhauser et al. | Dec 1997 | A |
5700285 | Myers et al. | Dec 1997 | A |
5702421 | Schneidt | Dec 1997 | A |
5704910 | Humes | Jan 1998 | A |
5709224 | Behl et al. | Jan 1998 | A |
5709704 | Nott et al. | Jan 1998 | A |
5709707 | Lock et al. | Jan 1998 | A |
5722400 | Ockuly et al. | Mar 1998 | A |
5724975 | Negus et al. | Mar 1998 | A |
5725512 | Swartz et al. | Mar 1998 | A |
5725552 | Kotula et al. | Mar 1998 | A |
5725568 | Hastings | Mar 1998 | A |
5733294 | Forber et al. | Mar 1998 | A |
5733302 | Myler et al. | Mar 1998 | A |
5735290 | Sterman et al. | Apr 1998 | A |
5749880 | Banas et al. | May 1998 | A |
5749883 | Halpern | May 1998 | A |
5749894 | Engelson | May 1998 | A |
5766219 | Horton | Jun 1998 | A |
5766246 | Mulhauser et al. | Jun 1998 | A |
5769816 | Barbut et al. | Jun 1998 | A |
5776097 | Massoud | Jul 1998 | A |
5776162 | Kleshinski | Jul 1998 | A |
5782860 | Epstein et al. | Jul 1998 | A |
5785679 | Abolfathi et al. | Jul 1998 | A |
5800454 | Jacobsen et al. | Sep 1998 | A |
5800457 | Gelbfish | Sep 1998 | A |
5800512 | Letnz et al. | Sep 1998 | A |
5807261 | Benaron et al. | Sep 1998 | A |
5810874 | Lefebvre | Sep 1998 | A |
5814028 | Swartz et al. | Sep 1998 | A |
5814029 | Hassett | Sep 1998 | A |
5814064 | Daniel | Sep 1998 | A |
5820591 | Thompson et al. | Oct 1998 | A |
5823198 | Jones et al. | Oct 1998 | A |
5830228 | Knapp et al. | Nov 1998 | A |
5833673 | Ockuly et al. | Nov 1998 | A |
5836913 | Orth et al. | Nov 1998 | A |
5836968 | Simon et al. | Nov 1998 | A |
5840027 | Swartz et al. | Nov 1998 | A |
5843118 | Sepetka et al. | Dec 1998 | A |
5846260 | Maahs | Dec 1998 | A |
5846261 | Kotula et al. | Dec 1998 | A |
5848969 | Panescu et al. | Dec 1998 | A |
5849005 | Garrison et al. | Dec 1998 | A |
5851232 | Lois | Dec 1998 | A |
5853422 | Huebsch et al. | Dec 1998 | A |
5855597 | Jayaraman | Jan 1999 | A |
5865791 | Whayne et al. | Feb 1999 | A |
5865802 | Yoon et al. | Feb 1999 | A |
5868702 | Stevens et al. | Feb 1999 | A |
5868708 | Hart et al. | Feb 1999 | A |
5876367 | Kaganov et al. | Mar 1999 | A |
5879296 | Ockuly et al. | Mar 1999 | A |
5879366 | Shaw et al. | Mar 1999 | A |
5882340 | Yoon | Mar 1999 | A |
5885258 | Sachdeva et al. | Mar 1999 | A |
5891558 | Bell et al. | Apr 1999 | A |
5895399 | Barbut et al. | Apr 1999 | A |
5902289 | Swartz et al. | May 1999 | A |
5904680 | Kordis et al. | May 1999 | A |
5904703 | Gilson | May 1999 | A |
5906207 | Shen | May 1999 | A |
5910154 | Tsugita et al. | Jun 1999 | A |
5911734 | Tsugita et al. | Jun 1999 | A |
5916236 | Moer et al. | Jun 1999 | A |
5925060 | Forber | Jul 1999 | A |
5925063 | Khosravi | Jul 1999 | A |
5925074 | Gingras et al. | Jul 1999 | A |
5925075 | Myers et al. | Jul 1999 | A |
5928192 | Maahs | Jul 1999 | A |
5928260 | Chin et al. | Jul 1999 | A |
5931818 | Werp et al. | Aug 1999 | A |
5935145 | Villar et al. | Aug 1999 | A |
5935147 | Kensey et al. | Aug 1999 | A |
5935148 | Villar et al. | Aug 1999 | A |
5941249 | Maynard | Aug 1999 | A |
5941896 | Kerr | Aug 1999 | A |
5944738 | Amplatz et al. | Aug 1999 | A |
5947997 | Pavcnik et al. | Sep 1999 | A |
5951589 | Epstein et al. | Sep 1999 | A |
5951599 | McCrory | Sep 1999 | A |
5954694 | Sunseri | Sep 1999 | A |
5954767 | Pajotin et al. | Sep 1999 | A |
5957940 | Tanner et al. | Sep 1999 | A |
5961545 | Lentz et al. | Oct 1999 | A |
5976174 | Ruiz | Nov 1999 | A |
5980514 | Kupiecki et al. | Nov 1999 | A |
5980555 | Barbut et al. | Nov 1999 | A |
5989281 | Barbut et al. | Nov 1999 | A |
5993469 | McKenzie et al. | Nov 1999 | A |
5993483 | Gianotti | Nov 1999 | A |
5997557 | Barbut et al. | Dec 1999 | A |
6004280 | Buck et al. | Dec 1999 | A |
6004348 | Banas et al. | Dec 1999 | A |
6007523 | Mangosong | Dec 1999 | A |
6007557 | Ambrisco et al. | Dec 1999 | A |
6010517 | Baccaro | Jan 2000 | A |
6010522 | Barbut et al. | Jan 2000 | A |
6013093 | Nott et al. | Jan 2000 | A |
6024751 | Lovato et al. | Feb 2000 | A |
6024754 | Engelson | Feb 2000 | A |
6024755 | Addis | Feb 2000 | A |
6024756 | Huebsch et al. | Feb 2000 | A |
6027520 | Tsugita et al. | Feb 2000 | A |
6033420 | Hahnen | Mar 2000 | A |
6036720 | Abrams et al. | Mar 2000 | A |
6042598 | Tsugita et al. | Mar 2000 | A |
6048331 | Tsugita et al. | Apr 2000 | A |
6051014 | Jang | Apr 2000 | A |
6051015 | Maahs | Apr 2000 | A |
6056720 | Morse | May 2000 | A |
6063070 | Eder | May 2000 | A |
6063113 | Kavteladze et al. | May 2000 | A |
6066126 | Li et al. | May 2000 | A |
6068621 | Balceta et al. | May 2000 | A |
6074357 | Kaganov et al. | Jun 2000 | A |
6076012 | Swanson et al. | Jun 2000 | A |
6079414 | Roth | Jun 2000 | A |
6080182 | Shaw et al. | Jun 2000 | A |
6080183 | Tsugita et al. | Jun 2000 | A |
6083239 | Addis | Jul 2000 | A |
6090084 | Hassett et al. | Jul 2000 | A |
6096052 | Callister et al. | Aug 2000 | A |
6096053 | Bates et al. | Aug 2000 | A |
6110243 | Wnenchak et al. | Aug 2000 | A |
6123715 | Amplatz | Sep 2000 | A |
6124523 | Banas et al. | Sep 2000 | A |
6132438 | Fleischman et al. | Oct 2000 | A |
6135991 | Muni et al. | Oct 2000 | A |
6136016 | Barbut et al. | Oct 2000 | A |
6139527 | Laufer et al. | Oct 2000 | A |
6139573 | Sogard et al. | Oct 2000 | A |
6152144 | Lesh et al. | Nov 2000 | A |
6152946 | Broome et al. | Nov 2000 | A |
6156055 | Ravenscroft | Dec 2000 | A |
6159195 | Ha et al. | Dec 2000 | A |
6161543 | Cox et al. | Dec 2000 | A |
6168615 | Ken et al. | Jan 2001 | B1 |
6171329 | Shaw et al. | Jan 2001 | B1 |
6179859 | Bates et al. | Jan 2001 | B1 |
6193739 | Chevillon et al. | Feb 2001 | B1 |
6203531 | Ockuly et al. | Mar 2001 | B1 |
6206907 | Marino et al. | Mar 2001 | B1 |
6214029 | Thill et al. | Apr 2001 | B1 |
6221092 | Koike et al. | Apr 2001 | B1 |
6231561 | Frazier et al. | May 2001 | B1 |
6231589 | Wessman et al. | May 2001 | B1 |
6235045 | Barbut et al. | May 2001 | B1 |
6245012 | Kleshinski | Jun 2001 | B1 |
6251122 | Tsukernik | Jun 2001 | B1 |
6258115 | Dubrul | Jul 2001 | B1 |
6267772 | Mulhauser et al. | Jul 2001 | B1 |
6267776 | O'Connell | Jul 2001 | B1 |
6270490 | Hahnen | Aug 2001 | B1 |
6270530 | Eldridge et al. | Aug 2001 | B1 |
6270902 | Tedeschi et al. | Aug 2001 | B1 |
6277138 | Levinson et al. | Aug 2001 | B1 |
6285898 | Ben-Haim | Sep 2001 | B1 |
6290674 | Roue et al. | Sep 2001 | B1 |
6290708 | Kugel et al. | Sep 2001 | B1 |
6312407 | Zadno-Azizi et al. | Nov 2001 | B1 |
6319251 | Tu et al. | Nov 2001 | B1 |
6328727 | Frazier et al. | Dec 2001 | B1 |
6328755 | Marshall | Dec 2001 | B1 |
6342062 | Suon et al. | Jan 2002 | B1 |
6346116 | Brooks et al. | Feb 2002 | B1 |
6346895 | Lee et al. | Feb 2002 | B1 |
6361545 | Macoviak et al. | Mar 2002 | B1 |
6364895 | Greenhalgh | Apr 2002 | B1 |
6368338 | Kónya et al. | Apr 2002 | B1 |
6371971 | Tsugita et al. | Apr 2002 | B1 |
6375670 | Greenhalgh | Apr 2002 | B1 |
6391044 | Yadav et al. | May 2002 | B1 |
6398803 | Layne et al. | Jun 2002 | B1 |
6402746 | Whayne et al. | Jun 2002 | B1 |
6402771 | Palmer et al. | Jun 2002 | B1 |
6402779 | Colone et al. | Jun 2002 | B1 |
6419669 | Frazier et al. | Jul 2002 | B1 |
6440152 | Gainor et al. | Aug 2002 | B1 |
6443972 | Bosma et al. | Sep 2002 | B1 |
6447530 | Ostrovsky et al. | Sep 2002 | B1 |
6454775 | Demarais et al. | Sep 2002 | B1 |
6458145 | Ravenscroft et al. | Oct 2002 | B1 |
6464712 | Epstein et al. | Oct 2002 | B1 |
6468291 | Bates et al. | Oct 2002 | B2 |
6468301 | Amplatz et al. | Oct 2002 | B1 |
6485501 | Green | Nov 2002 | B1 |
6488689 | Kaplan et al. | Dec 2002 | B1 |
6511496 | Huter et al. | Jan 2003 | B1 |
6514280 | Gilson | Feb 2003 | B1 |
6517573 | Pollock et al. | Feb 2003 | B1 |
6533782 | Howell et al. | Mar 2003 | B2 |
6547760 | Samson et al. | Apr 2003 | B1 |
6547815 | Myers | Apr 2003 | B2 |
6551303 | Van Tassel et al. | Apr 2003 | B1 |
6551344 | Thill | Apr 2003 | B2 |
6558401 | Azizi | May 2003 | B1 |
6558405 | McInnes | May 2003 | B1 |
6558414 | Layne | May 2003 | B2 |
6562058 | Seguin et al. | May 2003 | B2 |
6569184 | Huter | May 2003 | B2 |
6569214 | Williams et al. | May 2003 | B2 |
6589214 | McGuckin et al. | Jul 2003 | B2 |
6589251 | Yee et al. | Jul 2003 | B2 |
6599308 | Amplatz | Jul 2003 | B2 |
6602271 | Adams et al. | Aug 2003 | B2 |
6623508 | Shaw et al. | Sep 2003 | B2 |
6641564 | Kraus | Nov 2003 | B1 |
6650923 | Lesh et al. | Nov 2003 | B1 |
6652555 | VanTassel et al. | Nov 2003 | B1 |
6652556 | VanTassel et al. | Nov 2003 | B1 |
6666861 | Grabek | Dec 2003 | B1 |
6689150 | Vantassel et al. | Feb 2004 | B1 |
6699260 | Dubrul et al. | Mar 2004 | B2 |
6699276 | Sogard et al. | Mar 2004 | B2 |
6702825 | Frazier et al. | Mar 2004 | B2 |
6712836 | Berg et al. | Mar 2004 | B1 |
6726701 | Gilson et al. | Apr 2004 | B2 |
6730108 | Van Tassel et al. | May 2004 | B2 |
6755812 | Peterson et al. | Jun 2004 | B2 |
6827737 | Hill et al. | Dec 2004 | B2 |
6837901 | Rabkin et al. | Jan 2005 | B2 |
6855153 | Saadat | Feb 2005 | B2 |
6911037 | Gainor et al. | Jun 2005 | B2 |
6932838 | Schwartz et al. | Aug 2005 | B2 |
6942653 | Quinn | Sep 2005 | B2 |
6949113 | Van Tassel et al. | Sep 2005 | B2 |
6958061 | Truckai et al. | Oct 2005 | B2 |
6994092 | van der Burg et al. | Feb 2006 | B2 |
7011671 | Welch | Mar 2006 | B2 |
7014645 | Greene, Jr. et al. | Mar 2006 | B2 |
7037321 | Sachdeva et al. | May 2006 | B2 |
7044134 | Khairkhahan et al. | May 2006 | B2 |
7097651 | Harrison et al. | Aug 2006 | B2 |
7128073 | van der Burg et al. | Oct 2006 | B1 |
7152605 | Khairkhahan et al. | Dec 2006 | B2 |
7169164 | Borillo et al. | Jan 2007 | B2 |
7179275 | McGuckin, Jr. et al. | Feb 2007 | B2 |
7226466 | Opolski | Jun 2007 | B2 |
7303526 | Sharkey et al. | Dec 2007 | B2 |
7323002 | Johnson et al. | Jan 2008 | B2 |
7597704 | Frazier et al. | Oct 2009 | B2 |
7678123 | Chanduszko | Mar 2010 | B2 |
7695425 | Schweich et al. | Apr 2010 | B2 |
7713282 | Frazier et al. | May 2010 | B2 |
7722641 | van der Burg et al. | May 2010 | B2 |
7727189 | VanTassel et al. | Jun 2010 | B2 |
7735493 | van der Burg et al. | Jun 2010 | B2 |
7780694 | Palmer et al. | Aug 2010 | B2 |
7799049 | Ostrovsky et al. | Sep 2010 | B2 |
7811300 | Feller, III et al. | Oct 2010 | B2 |
7811314 | Fierens et al. | Oct 2010 | B2 |
7862500 | Khairkhahan et al. | Jan 2011 | B2 |
7927365 | Fierens et al. | Apr 2011 | B2 |
7972359 | Kreidler | Jul 2011 | B2 |
8025495 | Hardert et al. | Sep 2011 | B2 |
8043329 | Khairkhahan et al. | Oct 2011 | B2 |
8052715 | Quinn et al. | Nov 2011 | B2 |
8062282 | Kolb | Nov 2011 | B2 |
8080032 | van der Burg et al. | Dec 2011 | B2 |
8097015 | Devellian | Jan 2012 | B2 |
8221384 | Frazier et al. | Jul 2012 | B2 |
8221445 | van Tassel et al. | Jul 2012 | B2 |
8287563 | Khairkhahan et al. | Oct 2012 | B2 |
8323309 | Khairkhahan et al. | Dec 2012 | B2 |
8388672 | Khairkhahan et al. | Mar 2013 | B2 |
8491623 | Vogel et al. | Jul 2013 | B2 |
8523897 | van der Burg et al. | Sep 2013 | B2 |
8535343 | van der Burg et al. | Sep 2013 | B2 |
8562509 | Bates | Oct 2013 | B2 |
8663273 | Khairkhahan et al. | Mar 2014 | B2 |
8685055 | VanTassel et al. | Apr 2014 | B2 |
8834519 | van der Burg et al. | Sep 2014 | B2 |
8845711 | Miles et al. | Sep 2014 | B2 |
9034006 | Quinn et al. | May 2015 | B2 |
9132000 | VanTassel et al. | Sep 2015 | B2 |
9168043 | van der Burg et al. | Oct 2015 | B2 |
9211124 | Campbell et al. | Dec 2015 | B2 |
9445895 | Kreidler | Sep 2016 | B2 |
9554806 | Larsen et al. | Jan 2017 | B2 |
9561037 | Fogarty et al. | Feb 2017 | B2 |
9561097 | Kim et al. | Feb 2017 | B1 |
9629636 | Fogarty et al. | Apr 2017 | B2 |
9730701 | Tischler et al. | Aug 2017 | B2 |
9883936 | Sutton | Feb 2018 | B2 |
9883963 | Sutton et al. | Feb 2018 | B2 |
9913652 | Bridgeman et al. | Mar 2018 | B2 |
9943299 | Khairkhahan et al. | Apr 2018 | B2 |
9943315 | Kaplan et al. | Apr 2018 | B2 |
10071181 | Penegor et al. | Sep 2018 | B1 |
10076335 | Zaver et al. | Sep 2018 | B2 |
10143458 | Kreidler | Dec 2018 | B2 |
20010000797 | Mazzocchi | May 2001 | A1 |
20010020181 | Layne | Sep 2001 | A1 |
20010034537 | Shaw et al. | Oct 2001 | A1 |
20010037141 | Yee et al. | Nov 2001 | A1 |
20020022860 | Borillo et al. | Feb 2002 | A1 |
20020035374 | Borillo et al. | Mar 2002 | A1 |
20020045931 | Sogard et al. | Apr 2002 | A1 |
20020062133 | Gilson et al. | May 2002 | A1 |
20020082638 | Porter et al. | Jun 2002 | A1 |
20020082675 | Myers | Jun 2002 | A1 |
20020099439 | Schwartz et al. | Jul 2002 | A1 |
20020111647 | Khairkhahan et al. | Aug 2002 | A1 |
20020138094 | Borillo et al. | Sep 2002 | A1 |
20020138097 | Ostrovsky et al. | Sep 2002 | A1 |
20020169475 | Gainor et al. | Nov 2002 | A1 |
20020177855 | Greene, Jr. et al. | Nov 2002 | A1 |
20030017775 | Dong et al. | Jan 2003 | A1 |
20030023262 | Welch | Jan 2003 | A1 |
20030023266 | Borillo et al. | Jan 2003 | A1 |
20030057156 | Peterson et al. | Mar 2003 | A1 |
20030060871 | Hill et al. | Mar 2003 | A1 |
20030120337 | Van Tassel et al. | Jun 2003 | A1 |
20030181942 | Sutton et al. | Sep 2003 | A1 |
20030191526 | Van Tassel et al. | Oct 2003 | A1 |
20030195555 | Khairkhahan et al. | Oct 2003 | A1 |
20030204203 | Khairkhahan et al. | Oct 2003 | A1 |
20030208214 | Loshakove et al. | Nov 2003 | A1 |
20030220667 | van der Burg et al. | Nov 2003 | A1 |
20040034366 | van der Burg et al. | Feb 2004 | A1 |
20040044361 | Frazier et al. | Mar 2004 | A1 |
20040049210 | VanTassel et al. | Mar 2004 | A1 |
20040093012 | Cully et al. | May 2004 | A1 |
20040098031 | van der Burg et al. | May 2004 | A1 |
20040122467 | VanTassel et al. | Jun 2004 | A1 |
20040127935 | VanTassel et al. | Jul 2004 | A1 |
20040158274 | WasDyke | Aug 2004 | A1 |
20040186486 | Roue et al. | Sep 2004 | A1 |
20040215230 | Frazier et al. | Oct 2004 | A1 |
20040220610 | Kreidler et al. | Nov 2004 | A1 |
20040220682 | Levine et al. | Nov 2004 | A1 |
20040230222 | van der Burg et al. | Nov 2004 | A1 |
20050004652 | van der Burg et al. | Jan 2005 | A1 |
20050015109 | Lichtenstein | Jan 2005 | A1 |
20050038470 | van der Burg et al. | Feb 2005 | A1 |
20050049573 | Van Tassel et al. | Mar 2005 | A1 |
20050070952 | Devellian | Mar 2005 | A1 |
20050113861 | Corcoran et al. | May 2005 | A1 |
20050125020 | Meade et al. | Jun 2005 | A1 |
20050177182 | van der Burg et al. | Aug 2005 | A1 |
20050203568 | Burg et al. | Sep 2005 | A1 |
20050283186 | Berrada et al. | Dec 2005 | A1 |
20050288704 | Cartier et al. | Dec 2005 | A1 |
20060009800 | Christianson | Jan 2006 | A1 |
20060015136 | Besselink | Jan 2006 | A1 |
20060030877 | Martinez et al. | Feb 2006 | A1 |
20060052816 | Bates et al. | Mar 2006 | A1 |
20060100658 | Obana et al. | May 2006 | A1 |
20060155323 | Porter et al. | Jul 2006 | A1 |
20070066993 | Kreidler | Mar 2007 | A1 |
20070083227 | van der Burg et al. | Apr 2007 | A1 |
20070083230 | Javois | Apr 2007 | A1 |
20070135826 | Zaver | Jun 2007 | A1 |
20070150041 | Evans et al. | Jun 2007 | A1 |
20070156123 | Moll et al. | Jul 2007 | A1 |
20070162048 | Quinn et al. | Jul 2007 | A1 |
20070185471 | Johnson | Aug 2007 | A1 |
20080275536 | Zarins et al. | Nov 2008 | A1 |
20090005803 | Batiste | Jan 2009 | A1 |
20090062841 | Amplatz et al. | Mar 2009 | A1 |
20090099647 | Glimsdale et al. | Apr 2009 | A1 |
20090105747 | Chanduszko et al. | Apr 2009 | A1 |
20090112249 | Miles et al. | Apr 2009 | A1 |
20090254195 | Khairkhan et al. | Oct 2009 | A1 |
20090259295 | Rust | Oct 2009 | A1 |
20090318948 | Linder et al. | Dec 2009 | A1 |
20100004726 | Hancock et al. | Jan 2010 | A1 |
20100049238 | Simpson | Feb 2010 | A1 |
20100106178 | Obermiller et al. | Apr 2010 | A1 |
20100324585 | Miles et al. | Dec 2010 | A1 |
20110054515 | Bridgeman et al. | Mar 2011 | A1 |
20110082495 | Ruiz | Apr 2011 | A1 |
20110098525 | Kermode et al. | Apr 2011 | A1 |
20110218566 | van der Burg et al. | Sep 2011 | A1 |
20110301630 | Hendriksen et al. | Dec 2011 | A1 |
20120029553 | Quinn et al. | Feb 2012 | A1 |
20120035643 | Khairkhahan | Feb 2012 | A1 |
20120065662 | van der Burg et al. | Mar 2012 | A1 |
20120125619 | Wood et al. | May 2012 | A1 |
20120172654 | Bates | Jul 2012 | A1 |
20120172927 | Campbell et al. | Jul 2012 | A1 |
20120239077 | Zaver et al. | Sep 2012 | A1 |
20120239083 | Kreidler | Sep 2012 | A1 |
20120245619 | Guest | Sep 2012 | A1 |
20120283585 | Werneth et al. | Nov 2012 | A1 |
20120283773 | Van Tassel et al. | Nov 2012 | A1 |
20120316584 | Miles | Dec 2012 | A1 |
20120323267 | Ren | Dec 2012 | A1 |
20130006343 | Kassab et al. | Jan 2013 | A1 |
20130012982 | Khairkhahan et al. | Jan 2013 | A1 |
20130018413 | Oral et al. | Jan 2013 | A1 |
20130090684 | Van Bladel | Apr 2013 | A1 |
20130110154 | van der Burg et al. | May 2013 | A1 |
20130165735 | Khairkhahan et al. | Jun 2013 | A1 |
20130211492 | Schneider et al. | Aug 2013 | A1 |
20130331884 | Van der Burg et al. | Dec 2013 | A1 |
20140005714 | Quick | Jan 2014 | A1 |
20140018841 | Peiffer et al. | Jan 2014 | A1 |
20140039536 | Cully et al. | Feb 2014 | A1 |
20140046360 | van der Burg et al. | Feb 2014 | A1 |
20140081314 | Zaver et al. | Mar 2014 | A1 |
20140100596 | Rudman et al. | Apr 2014 | A1 |
20140142612 | Li et al. | May 2014 | A1 |
20140148842 | Khairkhahan et al. | May 2014 | A1 |
20140163605 | VanTassel et al. | Jun 2014 | A1 |
20140188157 | Clark | Jul 2014 | A1 |
20140303719 | Cox et al. | Oct 2014 | A1 |
20140336612 | Frydlewski et al. | Nov 2014 | A1 |
20140336699 | van der Burg et al. | Nov 2014 | A1 |
20150005810 | Center et al. | Jan 2015 | A1 |
20150039021 | Khairkhahan et al. | Feb 2015 | A1 |
20150080903 | Dillard et al. | Mar 2015 | A1 |
20150196300 | Tischler et al. | Jul 2015 | A1 |
20150230909 | Zaver et al. | Aug 2015 | A1 |
20150238197 | Quinn et al. | Aug 2015 | A1 |
20150305727 | Karimov et al. | Oct 2015 | A1 |
20150313604 | Roue et al. | Nov 2015 | A1 |
20150313605 | Griffin | Nov 2015 | A1 |
20150327979 | Quinn et al. | Nov 2015 | A1 |
20150374491 | Kreidler | Dec 2015 | A1 |
20160051358 | Sutton et al. | Feb 2016 | A1 |
20160058539 | VanTassel et al. | Mar 2016 | A1 |
20160066922 | Bridgeman et al. | Mar 2016 | A1 |
20160106437 | van der Burg et al. | Apr 2016 | A1 |
20160192942 | Strauss et al. | Jul 2016 | A1 |
20160287259 | Hanson et al. | Oct 2016 | A1 |
20160331382 | Center et al. | Nov 2016 | A1 |
20160374657 | Kreidler | Dec 2016 | A1 |
20170027552 | Turkington et al. | Feb 2017 | A1 |
20170042550 | Chakraborty et al. | Feb 2017 | A1 |
20170056166 | Ratz et al. | Mar 2017 | A1 |
20170100112 | van der Burg et al. | Apr 2017 | A1 |
20170181751 | Larsen et al. | Jun 2017 | A1 |
20170340336 | Osypka | Nov 2017 | A1 |
20180064446 | Figulla et al. | Mar 2018 | A1 |
20180070950 | Zaver et al. | Mar 2018 | A1 |
20180116678 | Melanson | May 2018 | A1 |
20180140412 | Sutton et al. | May 2018 | A1 |
20180140413 | Quinn et al. | May 2018 | A1 |
20180250014 | Melanson et al. | Sep 2018 | A1 |
20180310925 | Inouye | Nov 2018 | A1 |
20190021711 | Li | Jan 2019 | A1 |
20190059876 | Decker | Feb 2019 | A1 |
20190083075 | Onushko | Mar 2019 | A1 |
20190090884 | Bowman | Mar 2019 | A1 |
20190090885 | Zhou | Mar 2019 | A1 |
20190183512 | Subramaniam | Jun 2019 | A1 |
20190209178 | Richter | Jul 2019 | A1 |
20190209180 | Kealey | Jul 2019 | A1 |
20190223883 | Anderson et al. | Jul 2019 | A1 |
20190374229 | Anderson | Dec 2019 | A1 |
20200107836 | O'Halloran | Apr 2020 | A1 |
20200121324 | O'Halloran | Apr 2020 | A1 |
20200187952 | Walsh | Jun 2020 | A1 |
20200253613 | Pan | Aug 2020 | A1 |
20200390428 | Lee | Dec 2020 | A1 |
Number | Date | Country |
---|---|---|
1399571 | Feb 2003 | CN |
202143640 | Feb 2012 | CN |
106859722 | Jun 2017 | CN |
10201004476 | Mar 2012 | DE |
1523957 | Apr 2005 | EP |
1595504 | Nov 2005 | EP |
2074953 | Jan 2009 | EP |
2481381 | Aug 2012 | EP |
2928420 | Oct 2015 | EP |
3072461 | Sep 2016 | EP |
3372173 | Sep 2018 | EP |
2003532457 | Nov 2003 | JP |
2005324019 | Nov 2005 | JP |
2007513684 | May 2007 | JP |
2009160402 | Jul 2009 | JP |
2012501793 | Jan 2012 | JP |
9313712 | Jul 1993 | WO |
9504132 | Feb 1995 | WO |
9522359 | Aug 1995 | WO |
9601591 | Jan 1996 | WO |
9640356 | Dec 1996 | WO |
9721402 | Jun 1997 | WO |
9726939 | Jul 1997 | WO |
9728749 | Aug 1997 | WO |
9735522 | Oct 1997 | WO |
9802100 | Jan 1998 | WO |
9817187 | Apr 1998 | WO |
9822026 | May 1998 | WO |
9823322 | Jun 1998 | WO |
9827868 | Jul 1998 | WO |
9905977 | Feb 1999 | WO |
9907289 | Feb 1999 | WO |
9908607 | Feb 1999 | WO |
9923976 | May 1999 | WO |
9925252 | May 1999 | WO |
9930640 | Jun 1999 | WO |
9944510 | Sep 1999 | WO |
9959479 | Nov 1999 | WO |
0001308 | Jan 2000 | WO |
0016705 | Mar 2000 | WO |
0027292 | May 2000 | WO |
0035352 | Jun 2000 | WO |
0053120 | Sep 2000 | WO |
0067669 | Nov 2000 | WO |
0108743 | Feb 2001 | WO |
0115629 | Mar 2001 | WO |
0121247 | Mar 2001 | WO |
0126726 | Apr 2001 | WO |
0130266 | May 2001 | WO |
0130267 | May 2001 | WO |
0130268 | May 2001 | WO |
0170119 | Sep 2001 | WO |
0215793 | Feb 2002 | WO |
0224106 | Mar 2002 | WO |
02071977 | Sep 2002 | WO |
03007825 | Jan 2003 | WO |
03008030 | Jan 2003 | WO |
03032818 | Apr 2003 | WO |
2004012629 | Feb 2004 | WO |
2007044536 | Apr 2007 | WO |
2010024801 | Mar 2010 | WO |
2010081033 | Jul 2010 | WO |
2013060855 | May 2013 | WO |
2013159065 | Oct 2013 | WO |
2014011865 | Jan 2014 | WO |
2014018907 | Jan 2014 | WO |
2014089129 | Jun 2014 | WO |
201406239 | Jul 2014 | WO |
2015164836 | Oct 2015 | WO |
2016087145 | Jun 2016 | WO |
2018017935 | Jan 2018 | WO |
2018187732 | Oct 2018 | WO |
2019084358 | May 2019 | WO |
Entry |
---|
International Search Report and Written Opinion dated Aug. 3, 2004 for International Application No. PCT/US2004/008109. |
International Search Report and Written Opinion dated Feb. 15, 2000 for International Application No. PCT/US99/26325. |
International Search Report dated May 20, 2003 for International Application No. PCT/US02/33808. |
Written Opinion dated Nov. 17, 2003 for International Application No. PCT/US/02/33808. |
International Search Report and Written Opinion dated Aug. 21, 2018 for International Application No. PCT/US2018/029684. |
Cragg et al., “A New Percutaneous Vena Cava Filter,” American Journal of Radiology, Sep. 1983, pp. 601-604, vol. 141. |
Cragg et al., “Nonsurgical Placement of Arterial Endoprostheses: A New Technique Using Nitinol Wire,” Radiology, Apr. 1983, pp. 261-263, vol. 147, No. 1. |
Lock et al., “Transcatheter Closure of Atrial Septal Defects.” Circulation, May 1989, pp. 1091-1099, vol. 79, No. 5. |
Lock et al., “Transcatheter Umbrella Closure of Congenital Heart Defects,” Circulation, Mar. 1987, pp. 593-599, vol. 75, No. 3. |
Rashkind et al., “Nonsurgical closure of patent ductus arteriosus: clinical application of the Rashkind PDA Occluder System,” Circulation, Mar. 1987, pp. 583-592, vol. 75, No. 3. |
Rosengart et al., “Percutaneous and Minimally Invasive Valve Procedures,” Circulation, Apr. 1, 2008, pp. 1750-1767, vol. 117. |
Ruttenberg, “Nonsurgical Therapy of Cardiac Disorders,” Pediatric Consult, 1986, Pages not numbered, vol. 5, No. 2. |
Sugita et al., “Nonsurgical Implantations of a Vascular Ring Prosthesis Using Thermal Shape Memory Ti/Ni Alloy (Nitinol Wire),” Trans. Am. Soc. Artif. Intern. Organs, 1986, pp. 30-34, vol. XXXII. |
Wessel et al., “Outpatient Closure of the Patent Ductus Arteriousus,” Circulation, 1988, pp. 1068-1071, vol. 77, No. 5. |
Cline, “File: Fish hooks.jpg,” Wikipedia foundation , Inc., San Francisco, CA, Jun. 2007; p. 1 of 4; available online at http://en.wikipedia.org/wiki/File:Fish_hooks.jpg; last accessed Oct. 5, 2012. |
International Search Report and Written Opinion dated Apr. 22, 2014 for International Application No. PCT/US2013/078454. |
Aryana et al., “Incomplete Closure of the Left Atrial Appendage: Implication and Management.” Curr Cardiol Rep., 18(9):82, 2016. |
Delurgio, “Device-Associated Thrombus and Peri-Device Leak Following Left Atrial Appendage Closure with the Amplatzer Cardiac Plug.” JACC: Cardiovascular Interventions, 10(4): 400-402, 2017. |
University of Minnesota. Atlas of Human Cardiac Anatomy, Left Atrium. Retrieved from http://www.vhlab.umn.edu/atlas/left-atrium/left-atrial-appendage/index.shtml. Accessed 2017. Downloaded 2019. |
Saw et al., “Incidence and Clinical Impact of Device-Associated Thrombus and Peri-Device Leak following Left Atrial Appendage Closure with the Amplatzer Cardiac Plug.” JACC: Cardiovascular Intervention. 10(4): 391-399, 2017. |
Romero et al., “Left Atrial Appendage Closure Devices,” Clinical Medicine Insights: Cardiology, vol. 8, pp. 45-52, 2014. |
International Search Report and Written Opinion dated Oct. 27, 2017 for International Application No. PCT/US2017/048150. |
International Search Report and Written Opinion dated Jan. 21, 2019 for International Application No. PCT/US2018/051953. |
International Search Report and Written Opinion dated Oct. 13, 2016 for International Application No. PCT/US2016/043363. |
International Search Report and Written Opinion dated Mar. 17, 20, for International Application No. PCT/US2019/065243. |
International Search Report and Written Opinion dated Sep. 9, 2019 for International Application No. PCT/US2019/033698. |
Blackshear et al; “Appendage Obliteration to Reduce Stroke in Cardiac Surgical Patients with Atrial Fibrillation”, Ann. Thoracic Surgery, pp. 755-759, 1996. |
Lindsay, “Obliteration of the Left Atrial Appendage: A Concept Worth Testing”, Ann. Thoracic Surgery, 1996. |
Invitation To Pay Additional Fees dated Feb. 22, 2019 for International Application No. PCT/US2018/066163. |
International Search Report and Written Opinion dated Oct. 23, 2020 for International Application No. PCT/US2020/042192. |
Number | Date | Country | |
---|---|---|---|
20210015491 A1 | Jan 2021 | US |
Number | Date | Country | |
---|---|---|---|
62875040 | Jul 2019 | US |